Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9077 | 0.97 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL5256004 | 0.97 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL2092461 | 0.97 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL4490456 | 0.97 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL5857530 | 0.95 | HRH3 (0.75) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL1649755 | 0.95 | HRH3 (0.75) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL25335245 | 0.94 | — | — | |
| SCHEMBL9128 | 0.92 | — | — | |
| SCHEMBL9399 | 0.89 | HRH3 (0.65) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL1098239 | 0.89 | HRH3 (0.65) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017198756-A1 | QUINOLINE COMPOUNDS FOR INCREASING INSULINE RELEASE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-11-23 | — | — | WO | claimed |
| EP-3246028-A1 | QUINOLINE COMPOUNDS FOR INCREASING INSULINE RELEASE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-11-22 | — | — | EP | claimed |
| US-9238640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2016-01-19 | — | — | US | claimed |
| WO-2013175281-A1 | USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-11-28 | — | — | WO | claimed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | claimed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | claimed |
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | claimed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | claimed |
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| WO-2003053960-A2 | QUINLINE DERIVATES AND THEIR USE AS MEK INHIBITORS | ASTRAZENECA AB (SE) | 2003-07-03 | — | — | WO | claimed |
| WO-2003047584-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | claimed |
| WO-2003047585-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BENZOFURANYL SUBSTITUTED 3-CYANOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SOLID TUMOURS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | claimed |
| WO-2003045943-A1 | QUINAZOLINE COMPOUNDS WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | claimed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | claimed |
| WO-2002030924-A9 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | claimed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | claimed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | HRH3 2586/4885MAPT 1238/4885CYP1A2 4765/4885 |
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | NQO2, CCNI, F12 | HRH3 169/4885MAPT 3387/4885CYP1A2 546/4885 |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | HRH3 1540/4885MAPT 2027/4885CYP1A2 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.